Enrollment progressing in BBI-355 POTENTIATE and BBI-825 STARMAP clinical trials, with initial proof-of-concept data expected in the second half of 2025 Cash position of $167 million, with operating ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback